Skip to main content

Peanut Allergy clinical trials at UCSF
4 in progress, 0 open to eligible people

  • AR101 Real-World Open-Label Extension Study

    Sorry, in progress, not accepting new patients

    This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.

    San Francisco, California and other locations

  • Long-term Safety Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

    Sorry, accepting new patients by invitation only

    The purpose of this study is to assess AR101's safety and tolerability over an extended dosing period.

    San Francisco, California and other locations

  • PALISADE Follow-on Study (ARC004)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through characterized oral desensitization immunotherapy (CODIT) in peanut-allergic children and adults who have completed the ARC003 study.

    San Francisco, California and other locations

  • Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

    Sorry, not currently recruiting here

    The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).

    San Francisco, California and other locations

Last updated: